Regeneron Pharmaceuticals (REGN) EBITDA Margin (2009 - 2026)

Regeneron Pharmaceuticals' EBITDA Margin history runs 18 years deep, the most recent figure standing at 17.83% for Q1 2026.

• On a quarterly basis, EBITDA Margin fell 170.0% year-over-year to 17.83% in Q1 2026; TTM through Mar 2026 was 24.32%, a 287.0% decrease from a year earlier, with the FY2025 full-year figure at 24.95%, down 315.0% from the prior year.
• EBITDA Margin eased to 17.83% in Q1 2026 per REGN's latest filing, from 22.65% in the prior quarter.
• Across five years, EBITDA Margin topped out at 2517.0% in Q1 2022 and bottomed at 17.83% in Q1 2026.
• The 5-year median for EBITDA Margin is 29.94% (2023), against an average of 240.97%.
• Across the five-year window, EBITDA Margin soared 247300 bps in 2022 and sank 248706 bps in 2023, its largest moves.
• Year by year, EBITDA Margin stood at 1146.8% in 2022, then slumped by 98 bps to 28.33% in 2023, then slipped by 8 bps to 26.13% in 2024, then decreased by 13 bps to 22.65% in 2025, then decreased by 21 bps to 17.83% in 2026.
• Per Business Quant, the three latest REGN EBITDA Margin figures stand at 17.83% (Q1 2026), 22.65% (Q4 2025), and 27.35% (Q3 2025).